CTS-2016

N/A

Report date: 2024/11/28 15:05:23
NME

Base Information

Drug NameCTS-2016
Drug Alias NameCTS-2016
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsAXL receptor tyrosine kinaseTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCytosinLab Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesCytosinLab Therapeutics Co Ltd
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A